Semaglutide, a GLP-1 receptor agonist, may contribute to the reactivation of neurocysticercosis (NCC), but there is limited direct evidence linking GLP-1 agonists to this effect, warranting further research. The gene discussed is GLP1R; the disease is cysticercosis.